Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients

Journal of Interferon Research
R KurzrockJ U Gutterman

Abstract

Combinations of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) demonstrate synergistic antiproliferative activity in vitro. Therefore, we initiated a clinical study of recombinant TNF-alpha (rTNF-alpha) and rIFN-gamma combination therapy in humans. Twenty-five patients with metastatic cancer received both rTNF-alpha and rIFN-gamma by intramuscular injection for 5 consecutive days every 2 weeks for a total of 4 weeks. The dose levels were 5/5, 10/5, 10/10, 25/10, 25/25, 50/25, 50/50, 75/50, and 75/75 micrograms/m2 per day of rTNF-alpha/rIFN-gamma. A minimum of 2 patients were entered sequentially at each dose level. If the first 2-week cycle of therapy was well tolerated, the dose was increased to the next highest dose level during the second 2-week cycle. Fever, chills, and fatigue were observed at all doses. Severity of symptoms corresponded to increasing dose levels. Although TNF is identical to a molecule known as "cachectin," the vast majority of our patients did not lose weight while on study. However, alterations in lipid metabolism occurred and were manifested by a median change in triglyceride values of +40 mg/dl (range, -130 to +318 mg/dl), and in cholesterol values of -30 mg/dl (range, -103 t...Continue Reading

References

Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Jul 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockJ U Gutterman
Feb 12, 1987·The New England Journal of Medicine·B Beutler, A Cerami
Oct 24, 1986·Science·K J TraceyJ D Albert
Aug 26, 1982·Nature·P W Gray, D V Goeddel
Nov 1, 1984·The New England Journal of Medicine·K A FoonJ Zeffren
Jan 5, 1984·The New England Journal of Medicine·J R QuesadaJ U Gutterman
Mar 6, 1986·Nature·H D HollandM McCaffrey
Nov 1, 1961·Clinical Pharmacology and Therapeutics·D A KARNOFSKY

❮ Previous
Next ❯

Citations

Jan 1, 1991·Biotherapy·T Taguchi, Y Sohmura
Jun 8, 2000·Immunity·M K Slifka, J L Whitton
Jun 21, 2014·Future Oncology·Meaghan L KhanMitesh J Borad
Apr 1, 1992·International Journal of Immunopharmacology·J E Talmadge
Oct 1, 1992·Medical Hypotheses·R S Smith
Jun 28, 2016·Journal of Translational Medicine·Jing ShenChi Hin Cho
Jul 27, 2001·Cephalalgia : an International Journal of Headache·R H KemperG J Ter Horst
Nov 1, 2011·Oncotarget·Nicholas J RobertsMatthias Holdhoff
Jan 1, 1993·Medical Oncology and Tumor Pharmacotherapy·H F HavasM Goonewardene

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.